Carroll Financial Associates Inc. lifted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 1.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,029 shares of the company’s stock after purchasing an additional 91 shares during the quarter. Carroll Financial Associates Inc.’s holdings in Eli Lilly And Co were worth $810,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of LLY. Affiance Financial LLC acquired a new stake in Eli Lilly And Co in the fourth quarter valued at approximately $208,000. First Hawaiian Bank raised its holdings in Eli Lilly And Co by 38.2% in the fourth quarter. First Hawaiian Bank now owns 11,758 shares of the company’s stock valued at $1,360,000 after acquiring an additional 3,253 shares in the last quarter. MPS Loria Financial Planners LLC raised its holdings in Eli Lilly And Co by 9.1% in the fourth quarter. MPS Loria Financial Planners LLC now owns 2,046 shares of the company’s stock valued at $236,000 after acquiring an additional 170 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in Eli Lilly And Co by 2.0% in the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 9,297 shares of the company’s stock valued at $1,076,000 after acquiring an additional 180 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock valued at $23,660,000 after acquiring an additional 6,474 shares in the last quarter. 77.02% of the stock is currently owned by institutional investors and hedge funds.

In other Eli Lilly And Co news, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction on Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the sale, the senior vice president now owns 26,562 shares of the company’s stock, valued at $2,999,381.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the firm’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the sale, the insider now directly owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,702,736 shares of company stock worth $124,427,811. Insiders own 0.11% of the company’s stock.

Shares of LLY opened at $116.18 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. The company has a market cap of $124.16 billion, a PE ratio of 27.14, a price-to-earnings-growth ratio of 1.68 and a beta of 0.33. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $119.84.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm posted $1.05 earnings per share. Analysts anticipate that Eli Lilly And Co will post 5.59 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.22%. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

Several analysts recently weighed in on LLY shares. BMO Capital Markets raised their target price on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a report on Monday, December 24th. They noted that the move was a valuation call. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday, November 6th. Wolfe Research started coverage on shares of Eli Lilly And Co in a research note on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 price target on the stock. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research note on Wednesday, November 28th. Finally, Citigroup lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price target on the stock. in a research note on Sunday, December 2nd. Ten research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $111.50.

WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2019/01/12/carroll-financial-associates-inc-raises-stake-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.